Bristol Myers Squibb’s Zenbexus (iberdomide) also marked the first global FDA nod for a CELMoDs protein-degradation approach in multiple myeloma, according to separate coverage highlighting the drug class positioning and MRD-based regulatory path. The accelerated approval leverages a deeper remission endpoint rather than traditional response rates. Analysts framed the approval as a potential inflection point for competitive sequencing in second-line myeloma, where Zenbexus is designed to be used alongside daratumumab and dexamethasone. The reporting also points to an internal development roadmap for additional studies, including maintenance and earlier-line strategies. With a reported launch price and expectations for uptake, the decision sets up a near-term competitive test for combination regimens against established daratumumab-based standards.